Voyager Therapeutics to Participate in September Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2017 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases today announced its participation at the upcoming investor conferences:

• 2017 Wells Fargo Healthcare Conference, Boston, MA
  Date: September 6, 2017
  Time: 4:10 p.m. EDT
  Presenter:  Bernard Ravina, M.D., M.S., chief medical officer

• Morgan Stanley Global Healthcare Conference, New York City
  Date: September 11, 2017
  Time: 3:40 p.m. EDT
  Presenters:  Steven Paul, M.D., chief executive officer, Jane Henderson, chief financial officer

Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com.  The webcast will be archived for 30 days after the live event concludes.

Members of Voyager’s management team will also attend the following investor conferences for one-on-one meetings:

• Citi Annual Biotechnology Conference, Boston, MA
  Date: September 7, 2017

• Mizuho Biotechnology Conference 2017: CNS, Boston, MA
  Date: September 19, 2017

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases.  Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques.  The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.  Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School.  Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts.  For more information, please visit www.voyagertherapeutics.com.  Follow Voyager on LinkedIn.

Investor Relations:
Matt Osborne
Vice President of Investor Relations & Corporate Communications
857-259-5353
[email protected]

Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
[email protected]